All Photos(1)

Documents

N-059

Norbuprenorphine solution

Name: Norbuprenorphine solution
Brand: CERILLIAN

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₅H₃₅NO₄

CAS Number:

78715-23-8

Molecular Weight:

413.55

UNSPSC Code:

41116107

NACRES:

NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike^®/Snap-N-Shoot^®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant^®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

shipped in

wet ice

storage temp.

−20°C

SMILES string

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4)c56

InChI

1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1

InChI key

YOYLLRBMGQRFTN-IOMBULRVSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Certified Reference Materials

Controlled Substances & Illicit Drug Standards

Exclusive Savings

Pharmaceuticals, Illicit Drugs & Alcohol Standards

General description

A new Certified Spiking Solution^® suitable for use in clinical toxicology, forensic testing, or pain prescription monitoring.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.

Description

Pricing

signalword

Danger

hcodes

H225 - H301 + H311 + H331 - H370

pcodes

P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk_germany

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.

Marta Concheiro et al.

Therapeutic drug monitoring, 33(5), 619-626 (2011-08-24)

Buprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) pharmacokinetics after high-dose (14-20 mg) BUP sublingual tablet administration in three opioid-dependent pregnant

Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.

Hong K Kim et al.

Pediatrics, 130(6), e1700-e1703 (2012-11-07)

Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use

Unusual false-positive case of urinary screening for buprenorphine.

Giuseppe Lippi et al.

Journal of clinical laboratory analysis, 25(4), 244-245 (2011-07-26)

Buprenorphine is a centrally acting analgesic drug that is administered for the management of opioid dependence and as an analgesic drug for the treatment of chronic pain. The growing use of this substance has determined an increased need for laboratory

Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome.

Tor Seldén et al.

Forensic science international, 220(1-3), 284-290 (2012-05-09)

Buprenorphine is considered to have little respiratory side effects at therapeutic doses and the partial agonistic properties should produce a "ceiling effect" for respiratory depression at higher doses. Still, there are several reports on buprenorphine related deaths. Most deaths involve

Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment.

Kenneth F Ilett et al.

Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 7, 269-274 (2011-10-21)

The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4-24 mg)

View All Related Papers

Protocols

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 After Solid Phase Extraction (SPE) Using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

Using UHPLC/MS (TOF) for Detection of Drugs and Metabolites in Urine Following Optimized Enzymatic Hydrolysis Conditions

To optimize hydrolysis using β-glucuronidase, factors such as incubation time, temperature, hydrolysis pH, enzyme source, and enzyme concentration must be evaluated for each glucuronide metabolite to be analyzed.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service